Biotech Startups

HiRO is a full-service global contract research organization (CRO) that manages clinical trials for biotech companies, integrating regulatory strategy, clinical data science, clinical operations, medical monitoring, and quality into a single execution model. It operates across regions including North America and APAC and serves biotech sponsors developing drugs and therapies across therapeutic areas such as oncology and rare diseases.

1 investor

Hausen manufactures molecular diagnostic tests for detecting HPV, respiratory pathogens, and leukemia fusion genes using real-time PCR technology for clinical and laboratory use.

1 investor

Hawthorne Health operates a network of 12 community-based clinical research sites and offers in-home visits to conduct clinical trials, aiming to improve patient enrollment, retention, and protocol-compliant data. It serves study sponsors across therapeutic areas including cardiovascular, dermatology, immunology, neurology, and rare disease.</parameter> <parameter name="founders">[]

1 investor

HaystackAnalytics develops clinical genomics products for diagnostic labs and hospitals to deliver accurate and personalized diagnostics. The company specializes in genomics-based infectious disease diagnostics, particularly for tuberculosis detection in India.

1 investor

Kaipu (Kepu) operates a network of medical laboratories and inspection centers across China and Hong Kong, providing clinical diagnostic testing services, including infectious disease and COVID-19 testing. The company runs facilities in numerous cities and supports government public health and epidemic response efforts.

1 investor

Headlamp Health builds Lumos AI, a platform that consolidates fragmented patient data into a longitudinal view to support care, research, and therapeutic development in precision neuroscience. It serves clinicians, researchers, and drug developers working to match patients with the right treatments.

1 investor

Health Food Symmetry manufactures and supplies PhytoBiome, a patented whole-plant prebiotic ingredient derived from sugarcane, serving the global gut health, dietary supplements, functional foods, and animal health sectors. The company operates a GMP-certified Australian facility and sells through multiple revenue streams including B2B ingredient supply, consumer retail, and white-label partnerships.

1 investor

Health in Code is a genetic diagnostics laboratory that performs full genetic studies, variant interpretation, and clinical-genetic reporting, and develops and manufactures disease diagnostic kits for specialized labs. It serves healthcare professionals and hospitals managing patients with hereditary genetic diseases, with clients in over 30 countries.

1 investor

HealthOutlook applies life sciences and machine learning methods to predict health outcomes.

1 investor

Helaxy develops next-generation sequencing (NGS) testing solutions for hospitals and clinical laboratories, making molecular diagnostics more accessible and easier to implement in routine care.

1 investor

Helex is a biotech company whose team specializes in molecular biology, drug delivery, biomedical engineering, and nanotechnology research.

1 investor

Helical offers an AI platform for drug discovery that tunes bio foundation models to a customer's own biology and lab data, orchestrating them into ranked, mechanistically grounded candidate shortlists for target identification and biomarker discovery. It is built for biopharma R&D teams and provides model-agnostic harnesses, benchmarking, and enterprise deployment with data controls.

1 investor

Helix is a population genomics company that provides an end-to-end platform to integrate genomic data into clinical care, research, and therapeutic development. It partners with health systems, providers, payers, life sciences organizations, and patients to enable genetic screening and personalized healthcare at scale.

1 investor

HelloBiome helps product development teams incorporate microbiome science into formulation strategy, ingredient selection, and manufacturing for biology-driven consumer products. The company translates microbiome data and proprietary datasets into practical product decisions across skincare and personal care categories.

1 investor

Helogen (Odyssey Spaceworks) develops fully automated, AI-driven factories in orbit to manufacture high-value biomaterials that cannot be produced under Earth's gravity, leveraging microgravity for greater purity and scale. It targets human and planetary health applications and works with government, institutional research, and orbital infrastructure partners.

1 investor

1 investor

Helsinn is a global pharmaceutical company that develops and distributes supportive care medications for patients with cancer and chronic diseases. The company operates through a combination of direct sales in the United States and commercial partnerships internationally.

1 investor

Helus Pharma is a clinical-stage biopharmaceutical company developing small-molecule therapies for psychiatric and CNS conditions such as depression, anxiety, schizophrenia, and bipolar disorder. It focuses on advancing novel treatments for mental health disorders through clinical development and commercialization.

1 investor

Hemerion develops photonic drug-device combination therapies for treating glioblastomas and other brain tumors in clinical settings. The company combines photosensitizing drugs with innovative photonic systems designed to integrate into surgical workflows and selectively destroy tumor cells.

1 investor

Hemispherian is a clinical-stage pharmaceutical company developing small molecule drugs that target the TET2 enzyme as targeted therapies for aggressive cancers. Its lead compound GLIX1 is entering clinical development for glioblastoma, a cancer of the central nervous system.

1 investor

Hemo Group develops interventional medical devices for treating neuro-vascular diseases, including ischemic stroke, hemorrhagic stroke, and neuro access, with products such as the Afentta intracranial thrombectomy device. The company markets its devices across Europe, Asia, and the Middle East, with R&D conducted in the US.

1 investor

Hemostemix is a clinical-stage regenerative medicine company developing ACP-01, an investigational autologous (patient-derived) stem cell therapy for vascular and ischemic conditions such as critical limb ischemia, peripheral arterial disease, ischemic cardiomyopathy, and heart failure. The company runs Phase I and Phase II clinical programs and is publicly traded (TSXV: HEM | OTCQB: HMTXF).

1 investor

HemostOD engineers and manufactures universal (HLA-low) platelets using a proprietary platform that immortalizes hematopoietic progenitor cells and generates platelets via microfluidic bioreactors. The preclinical biotech targets applications in thrombocytopenia, tissue-targeted cargo delivery, regenerative medicine, and therapeutic stem cell culture.

1 investor

hemotune develops a magnetic nanoparticle platform for targeted magnetic separation in medical and biomanufacturing applications. The platform removes disease triggers and harmful agents from the bloodstream or processes biological materials with high selectivity and scalability.

1 investor